Summary:
This week on The Genetics Podcast, Patrick Short takes a solo deep dive into the current state of gene therapy ahead of next week’s live recording at ASHG. He explores the promise and limitations of adeno-associated virus (AAV) delivery, examples of gene therapies for neuromuscular diseases, and the challenges of balancing safety, cost, and commercial viability in rare diseases.
Show Notes:
0:00 Intro to The Genetics Podcast
00:59 Episode overview
02:50 Definition and scope of gene therapy
04:50 Gene therapy delivery via adeno-associated virus (AAV) and associated challenges and advantages
06:40 AAV-based gene therapy and other advanced therapies in spinal muscular atrophy (SMA)
10:29 Recent safety concerns around Sarepta Therapeutics’ AAV-based gene therapy for Duchenne muscular dystrophy (DMD)
19:30 Commercial viability challenges for rare disease gene therapy
24:26 Risk-benefit analysis of gene therapy for rare diseases
28:33 Considerations for optimizing AAV design and delivery routes
31:26 Alternative approaches for delivery using viral and non-viral methods
36:09 The future of AAV gene therapy
41:42 Closing remarks
Find out more
Update on Sarepta Therapeutics’ gene therapy for DMD (https://www.fiercepharma.com/pharma/sarepta-shares-more-elevidys-safety-data-response-patient-group-fda-petition)
Please consider rating and reviewing us on your chosen podcast listening platform!
https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link